122 results match your criteria brolucizumab


Cost-minimisation analysis of a treat-and-extend regimen with anti-VEGFs in patients with neovascular age-related macular degeneration.

Graefes Arch Clin Exp Ophthalmol 2021 Oct 13. Epub 2021 Oct 13.

Asc Academics, Professor Enno Dirk Wiersmastraat 5, Groningen, The Netherlands.

Purpose: Although intraocular anti-vascular endothelial growth factors (anti-VEGFs) are effective as treatment of neovascular age-related macular degeneration (nAMD), the (economic) burden on the healthcare system is considerable. A treat-and-extend (T&E) regimen is associated with a lower number of injections without compromising the effectiveness and can therefore help optimise nAMD treatment. This study investigates the per-patient costs associated with nAMD treatment, when using aflibercept, bevacizumab, or ranibizumab with a T&E regimen. Read More

View Article and Full-Text PDF
October 2021

Pitfalls in the Interpretation of Intraocular Inflammation in Response to Intravitreal Brolucizumab Injection.

Ocul Immunol Inflamm 2021 Oct 12:1-3. Epub 2021 Oct 12.

Swiss Eye Institute and Clinic for Vitreoretinal Diseases, Berner Augenklinik am Lindenhof-Spital, Bern, Switzerland.

View Article and Full-Text PDF
October 2021

Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration.

J Exp Pharmacol 2021 29;13:905-912. Epub 2021 Sep 29.

Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA.

Age-related macular degeneration (AMD) is the most common cause of legal blindness in developed countries. Neovascular (ie, wet) AMD is currently managed with intravitreal therapy. Traditional treatments (ie, bevacizumab, ranibizumab, aflibercept) provide high-efficacy therapy but can also require frequent dosing. Read More

View Article and Full-Text PDF
September 2021

Regression of aneurysmal type 1 neovascularization after brolucizumab injections.

Can J Ophthalmol 2021 Oct 1. Epub 2021 Oct 1.

Eye Clinic, Department of Biomedical and Clinical Science "Luigi Sacco", University of Milan, Milan, Italy.

View Article and Full-Text PDF
October 2021

Brolucizumab-associated intraocular inflammation in eyes without retinal vasculitis.

J Vitreoretin Dis 2021 Jul 15;5(4):326-332. Epub 2020 Dec 15.

Austin Retina Associates, Austin, TX.

Purpose: To analyze a series of eyes with brolucizumab-associated intraocular inflammation (IOI) without retinal vasculitis reported to the American Society of Retina Specialists (ASRS).

Methods: The ASRS Research and Safety in Therapeutics (ReST) Committee analyzed clinical characteristics from submitted reports of IOI after brolucizumab. Eyes with retinal vasculitis or that received intraocular antibiotics were excluded. Read More

View Article and Full-Text PDF

Initial Pro Re Nata Brolucizumab for Exudative AMD: The PROBE Study.

J Clin Med 2021 Sep 15;10(18). Epub 2021 Sep 15.

Service d'Ophtalmologie, Centre Hospitalier Universitaire de la Croix-Rousse, Hospices Civils de Lyon, Université Claude Bernard Lyon 1, 69004 Lyon, France.

The present study aimed to determine the efficacy and safety of pro re nata (PRN) intravitreal brolucizumab therapy for neovascular age-related macular degeneration (AMD) without a loading dose in the real-world setting. The PROBE study (Pro Re Nata Brolucizumab for Exudative AMD) is a retrospective, observational, multicentric study that included 27 treatment-naïve patients (27 eyes) with neovascular AMD who received PRN brolucizumab therapy with the treatment interval being at least 8 weeks, should the need for a second consecutive injection arise. The primary outcome measure was changed to best-corrected visual acuity (BCVA) over time. Read More

View Article and Full-Text PDF
September 2021

Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy.

Biomedicines 2021 Sep 5;9(9). Epub 2021 Sep 5.

Department of Ophthalmology, Faculty of Medicine, University of Yamanashi, Shimokato 1110, Chuo, Yamanashi 409-3821, Japan.

We compared the short-term outcomes between 3-monthly aflibercept and brolucizumab injections for treatment-naïve polypoidal choroidal vasculopathy (PCV). A total of 52 eyes were included. Patients received 3 monthly intravitreal aflibercept ( = 38) or intravitreal brolucizumab ( = 14). Read More

View Article and Full-Text PDF
September 2021

Brolucizumab in Neovascular Age-Related Macular Degeneration - Indian Real-World Experience: The BRAILLE Study.

Clin Ophthalmol 2021 7;15:3787-3795. Epub 2021 Sep 7.

Department of Vitreoretinal Services, Disha Eye Hospitals, Kolkata, West Bengal, India.

Purpose: To assess the short-term efficacy and safety profile of intravitreal brolucizumab injection in Indian eyes with neovascular age-related macular degeneration (nAMD) under real-world conditions.

Patients And Methods: This was a multicenter, retrospective chart review of 94 eyes of 94 patients with nAMD (treatment-naïve and switch-therapy) undergoing brolucizumab therapy. Re-treatment as per pro-re-nata protocol was performed based on fixed visual and tomographic criteria. Read More

View Article and Full-Text PDF
September 2021

Off-label intravitreal brolucizumab for recalcitrant diabetic macular edema: A real-world case series.

Am J Ophthalmol Case Rep 2021 Dec 1;24:101197. Epub 2021 Sep 1.

Department of Vitreoretinal Services, Disha Eye Hospitals, Kolkata, India.

Purpose: To report the efficacy of intravitreal injection (IVI) of brolucizumab for recalcitrant diabetic macular edema (DME) in a real-world setting.

Observations: This was a single-center, prospective uncontrolled non-randomized case series. Three eyes with recalcitrant DME, who have received a minimum of ten intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections, underwent IVI brolucizumab and were followed-up for minimum of 16 weeks. Read More

View Article and Full-Text PDF
December 2021

Visual acuity outcomes of anti-VEGF treatment for neovascular age-related macular degeneration in clinical trials.

Jpn J Ophthalmol 2021 Sep 7. Epub 2021 Sep 7.

Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Anti-VEGF treatment for neovascular age-related macular degeneration (nAMD) has been evaluated in clinical trials. To select the best anti-VEGF drug and the best treatment regimen for nAMD, a thorough understanding of the characteristics of each anti-VEGF drug and treatment regimen is essential. In this review, we summarized visual acuity (VA) changes in 30 previous clinical trials of anti-VEGF treatment for nAMD. Read More

View Article and Full-Text PDF
September 2021

Treatment of Neovascular Age-Related Macular Degeneration: An Economic Cost-Risk Analysis of Anti-VEGF agents.

Ophthalmol Retina 2021 Aug 25. Epub 2021 Aug 25.

Lerner College of Business and Economics, University of Delaware, Newark, DE USA.

Objective: To find the best cost-effective NVAMD treatment to improve vision while avoiding complications. The model is based on a cost-risk tradeoff analysis from policymakers' perspective.

Design: A powerful and flexible simulation models outcomes of 2 years of treatment with the four commonly used anti-VEGF drugs (bevacizumab, ranibizumab, aflibercept, and brolucizumab) across three injection protocols, building on prior findings that these drugs are non-inferior. Read More

View Article and Full-Text PDF

Three-Month Results of Brolucizumab Intravitreal Therapy in Patients with Wet Age-Related Macular Degeneration.

Int J Environ Res Public Health 2021 08 10;18(16). Epub 2021 Aug 10.

University Clinical Center, University Hospital Medical University of Silesia, 40-514 Katowice, Poland.

The purpose of the study was to evaluate changes in best corrected visual acuity, central retinal thickness, area and flow in the neovascular membrane and to compare therapeutic outcomes from baseline in patients who received three doses of Beovu (brolucizumab) at three-month follow-up.

Material And Methods: A prospective observational study conducted at the Prof. K. Read More

View Article and Full-Text PDF

Comparison of Syringes With Intravitreal Anti-VEGF Drugs: Particle Burden and Protein Aggregates in Brolucizumab, Aflibercept and Bevacizumab.

Transl Vis Sci Technol 2021 08;10(9):21

Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-University Munich, Germany.

Purpose: In a benchwork particle counting analytical evaluation, the number and type of particles in intravitreal injection formulations of three different agents against vascular endothelial growth factor were investigated.

Methods: Commercially available ready-to-use aflibercept and brolucizumab glass syringes, vials containing bevacizumab (off-label use in ophthalmology), and repackaged ready-to-use plastic syringes containing bevacizumab were tested without filtration. Total visible, subvisible, and nanoparticles numbers and size distributions were quantified using light obscuration, flow imaging, resonant mass measurement (RMM), tunable resistive pulse sensing, and dynamic light scattering. Read More

View Article and Full-Text PDF

Next-generation anti-VEGF agents for diabetic macular oedema.

Eye (Lond) 2021 Aug 9. Epub 2021 Aug 9.

Division of Ophthalmology, Tel Aviv Sourasky Medical Center, affiliated to Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

The treatment and outcomes of diabetic macular oedema (DMO) have improved with the introduction of intravitreal injections. However, real-world data reveal that the burden of DMO treatment causes large gaps in outcomes between randomized clinical trials and daily clinical practice. Long-lasting intravitreal drugs and devices for DMO might reduce this disparity by achieving optimal treatment due to more feasible injection regimens. Read More

View Article and Full-Text PDF

Molecular Features of Classic Retinal Drugs, Retinal Therapeutic Targets and Emerging Treatments.

Pharmaceutics 2021 Jul 20;13(7). Epub 2021 Jul 20.

IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Via Olgettina 60, 20132 Milan, Italy.

The management of exudative retinal diseases underwent a revolution due to the introduction of intravitreal treatments. There are two main classes of intravitreal drugs, namely anti-vascular endothelial growth factors (anti-VEGF) and corticosteroids molecules. The clinical course and the outcome of retinal diseases radically changed thanks to the efficacy of these molecules in determining the regression of the exudation and the restoration of the macular profile. Read More

View Article and Full-Text PDF

[Real-life experiences with Brolucizumab in recalcitrant neovascular age-related macular degeneration].

Ophthalmologe 2021 Aug 5. Epub 2021 Aug 5.

Augenzentrum am St. Franziskus-Hospital, Münster, Deutschland.

Background: Pivotal clinical trials have proven brolucizumab to be a potent intravitreal anti-vascular endothelial growth factor (VEGF) drug in patients with neovascular age-related macular degeneration (nAMD). Therefore, it seems to be a promising drug also in patients with recalcitrant nAMD. This article presents the results of patients who were switched to brolucizumab due to persistent fluid under previous anti-VEGF treatment. Read More

View Article and Full-Text PDF

A case of recalcitrant neovascular wet age-related macular degeneration treated with Intravitreal Brolucizumab.

Photodiagnosis Photodyn Ther 2021 Sep 22;35:102450. Epub 2021 Jul 22.

Department of Ophthalmology, Institute of Medical Sciences & SUM Hospital, SOA (deemed to be) University, 8-Kalinga Nagar, Bhubaneswar, 751003, India. Electronic address:

A 72-year-old male presented with loss of vision in left eye of 1 year duration. Patient had been diagnosed with wet neovascular age related macular degeneration in left eye and had received multiple injections of anti- vascular endothelial growth factor agents in past. Clinical and imaging studies showed persistent subretinal fluid. Read More

View Article and Full-Text PDF
September 2021

Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK.

Br J Ophthalmol 2021 Jul 22. Epub 2021 Jul 22.

Eye and Retina Surgeons, Camden Medical Centre, Singapore.

Purpose: To compare the efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy (PCV) over 96 weeks in the HAWK study.

Design: HAWK was a global, 2-year, randomised, double-masked, multicentre phase III trial in participants with neovascular age-related macular degeneration.

Methods: Of the Japanese participants with PCV, 39 received brolucizumab 6 mg and 30 received aflibercept 2 mg. Read More

View Article and Full-Text PDF

Evolving treatment paradigms for PCV.

Eye (Lond) 2021 Jul 14. Epub 2021 Jul 14.

Singapore National Eye Centre and Singapore Eye Research Institute, Singapore, Singapore.

Polypoidal choroidal vasculopathy (PCV) is a subtype of neovascular AMD (nAMD) that accounts for a significant proportion of nAMD cases worldwide, and particularly in Asia. Contemporary PCV treatment strategies have closely followed those used in typical nAMD, though there are significant gaps in knowledge on PCV management and it remains unclear if these strategies are appropriate. Current clinical trial data suggest intravitreal anti-vascular endothelial growth factor (VEGF) therapy alone or in combination with photodynamic therapy is effective in managing haemorrhage and exudation in PCV, although the optimal treatment interval, including as-needed and treat-and-extend approaches, is unclear. Read More

View Article and Full-Text PDF

Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes.

J Clin Med 2021 Jun 17;10(12). Epub 2021 Jun 17.

Berner Augenklinik am Lindenhofspital, 3012 Bern, Switzerland.

: The aim of this study was to evaluate the effect of switching treatment in eyes with neovascular age-related macular degeneration (nAMD) and treatment intervals of ≤6 weeks to brolucizumab. : In this prospective series, eyes with persisting retinal fluid under aflibercept or ranibizumab every 4-6 weeks were switched to brolucizumab. Visual acuity (BCVA), reading acuity (RA), treatment intervals, central subfield thickness (CST), and the presence of intra- and subretinal fluid were recorded over 6 months. Read More

View Article and Full-Text PDF

Real-World Experience with Brolucizumab in Wet Age-Related Macular Degeneration: The REBA Study.

J Clin Med 2021 Jun 23;10(13). Epub 2021 Jun 23.

Service d'Ophtalmologie, Centre Hospitalier Universitaire de la Croix-Rousse, Hospices Civils de Lyon, Université Claude Bernard Lyon 1, 69004 Lyon, France.

The aim of the present study was to determine the efficacy and safety of intravitreal brolucizumab therapy for neovascular age-related macular degeneration (AMD) in the real-world setting. The REBA study (real-world experience with brolucizumab in wet AMD) was a retrospective, observational, multicentric study that included 78 consecutive patients (105 eyes), with neovascular AMD, who received brolucizumab therapy. Both treatment-naive and switch-therapy patients were included. Read More

View Article and Full-Text PDF

Biomarkers in Early Response to Brolucizumab on Pigment Epithelium Detachment Associated with Exudative Age-Related Macular Degeneration.

Biomedicines 2021 Jun 10;9(6). Epub 2021 Jun 10.

Unit of Ophthalmology, Fondazione Policlinico A Gemelli, IRCCS, 00168 Rome, Italy.

Background: The purpose of this study was to describe early changes in the morphology of pigment epithelium detachments (PED) after an intravitreal injection of Brolucizumab into eyes with macular neovascularization secondary to exudative age-related macular degeneration (e-AMD).

Method: We included twelve eyes of 12 patients with PED secondary to e-AMD which were not responding to prior anti-VEGF treatments. An ophthalmic examination and an assessment of PED-horizontal maximal diameter (PED-HMD), PED-maximum high (PED-MH) and macular neovascularization (MNV) flow area (MNV-FA) by the means of structural optical coherence tomography (OCT) and OCT Angiography (OCT-A) were performed at baseline, as well as 1, 7, 14 and 30 days after the injection. Read More

View Article and Full-Text PDF

The Challenges of Treating Neovascular Age-Related Macular Degeneration.

Klin Monbl Augenheilkd 2021 Jul 1. Epub 2021 Jul 1.

Universitätsklinik für Augenheilkunde und Optometrie, Medizinische Universität Wien, Österreich.

Age-related macular degeneration (AMD) is one of the main causes of visual impairment and blindness in patients over 60 years in developed countries. Whilst no effective form of therapy is available for the dry form of AMD, intravitreal application of anti-VEGF substances is able to prevent the progression of neovascular AMD (nAMD) in most cases. Aside from the drugs ranibizumab, aflibercept and brolucizumab, other agents such as bevacizumab are often used off-label in order to save expense. Read More

View Article and Full-Text PDF

Trends in Endophthalmitis Associated With Intravitreal Injection of Anti-VEGF Agentsat a Tertiary Referral Center.

Ophthalmic Surg Lasers Imaging Retina 2021 06 1;52(6):319-326. Epub 2021 Jun 1.

Background And Objective: To report the incidence and clinical features of infectious endophthalmitis after intravitreal (IV) injection of anti-vascular endothelial growth factor inhibitors (VEGF) between 2018 and 2020 and to compare to prior rates.

Patients And Methods: Retrospective analysis of patients with endophthalmitis after anti-VEGF IV injections treated at Bascom Palmer Eye Institute between January 1, 2018, and December 31, 2020.

Results: Between 2018 and 2020, the rate of clinically diagnosed endophthalmitis was 0. Read More

View Article and Full-Text PDF

Brolucizumab for Choroidal Neovascular Membrane with Pigment Epithelial Tear and Subretinal Fluid.

J Clin Med 2021 May 30;10(11). Epub 2021 May 30.

Service d'Ophtalmologie, Centre Hospitalier Universitaire de la Croix-Rousse, Hospices Civils de Lyon, Université Claude Bernard Lyon 1, 69004 Lyon, France.

The aim of this study was to determine the utility of brolucizumab in the management of choroidal neovessels (CNV) with a retinal pigment epithelial (RPE) tear and subretinal fluid. We used a case series of patients with CNV who developed an RPE tear either spontaneously or following an intravitreal injection. All patients received intravitreal brolucizumab as primary or switch therapy. Read More

View Article and Full-Text PDF

Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis.

J Manag Care Spec Pharm 2021 Jun;27(6):743-752

Retina Consultants of Houston, Retina Consultants of America, and Blanton Eye Institute and Houston Methodist Hospital, Houston, TX.

Age-related macular degeneration (AMD) is a leading cause of blindness worldwide and is the most common cause of blindness in developed countries. Despite antivascular endothelial growth factor (anti-VEGF) therapy demonstrating improvements in visual and anatomical outcomes, unmet needs remain. Brolucizumab-dbll (ie, brolucizumab), a VEGF inhibitor for treatment of neovascular (wet) AMD and recently approved by the FDA for its treatment of wet AMD, attempts to mitigate treatment burden through less frequent injections. Read More

View Article and Full-Text PDF

Ocular Pharmacokinetics of Intravitreally Injected Protein Therapeutics: Comparison among Standard-of-Care Formats.

Mol Pharm 2021 06 20;18(6):2208-2217. Epub 2021 May 20.

Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, CH-4070 Basel, Switzerland.

The current standard of care for antivascular endothelial growth factor (VEGF) treatment requires frequent intravitreal (IVT) injections of protein therapeutics, as a result of limited retention within the eye. A thorough understanding of the determinants of ocular pharmacokinetics (PK) and its translation across species is an essential prerequisite for developing more durable treatments. In this work, we studied the ocular PK in macaques of the protein formats that comprise today's anti-VEGF standard of care. Read More

View Article and Full-Text PDF